AMBS LymPro Alzheimer’s Diagnostic Development S

AMBS >>LymPro Alzheimer’s Diagnostic Development Strategy/to Present at BIO Business Forum April 23rd

2013-04-15 07:30 ET - News Release



SUNNYVALE, Calif. -- (Business Wire)

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis, today announced that Chief Executive Officer Gerald E. Commissiong is presenting at the BIO Business Forum in Chicago on Tuesday, April 23, at 10:45 a.m. Central. The presentation will be held in the Chicago Cubs Room in McCormick Place.

“The BIO Business Forum is an outstanding venue for presenting the Amarantus story to global constituencies, including health care professionals, potential business partners and investors,” said Mr. Commissiong. “In addition to our presentation, the Forum provides an opportunity for one-on-one business development meetings and interaction with industry leaders through the Forum Partnering program.”

The BIO Business Forum is part of the BIO International Conference, which is being held April 22-26, 2013 at McCormick Place. The conference is sponsored and hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

About Amarantus

Amarantus is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property and licenses for the diagnosis of Parkinson’s disease and Alzheimer’s disease. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible progress of the MANF technology in testing for Parkinson’s disease, as well as statements about expectations, plans and prospects of the development of Amarantus’ diagnostic product candidates for Parkinson’s and Alzheimer’s disease. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks associated with development of therapeutic drug candidates, as well as the risks, uncertainties and assumptions relating to the development of Amarantus’ new product candidates, including those identified under “Risk Factors” in Amarantus’ most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.



Contacts:

Investor/Media Contact
LHA
Don Markley, Senior Vice President
310-691-7100
dmarkley@lhai.com


Source: Amarantus BioScience Holdings, Inc.